Sign in
6-K

Report of Foreign Issuer

Evaxion A/S Filed Acc 0001171843-26-007220

New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01

  • Detection of neoantigen-specific T cells directly ex vivo indicates strong EVX-01-induced immune responses

From the SEC's structured data for this filing